Cite
HARVARD Citation
He, S. et al. (n.d.). A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leukemia & lymphoma. 56 (5), pp. 1406-1415. [Online].